Ex vivo gene therapy for lysosomal storage disorders: future perspectives

References

• Platt FM, d’Azzo A, Davidson BL, et al. Lysosomal Storage diseases. Nat Rev Dis Primers. 2018;4(1):27. DOI:10.1038/s41572-018-0025-4
   PubMed Web of Science ®Google Scholar
• Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199(5):723–734.
   PubMed Web of Science ®Google Scholar
• Poswar FO, Vairo F, Burin M, et al. Lysosomal diseases: overview on current diagnosis and treatment. Genet Mol Biol. 2019;42(1 suppl 1):165–177. DOI:10.1590/1678-4685-gmb-2018-0159
   PubMed Web of Science ®Google Scholar
• Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017;118:109–134.
   PubMed Web of Science ®Google Scholar
• Scotto Rosato A, Krogsaeter EK, Jaślan D, et al. TPC2 rescues lysosomal storage in mucolipidosis type IV , Niemann–Pick type C1, and Batten disease. EMBO Mol Med. 2022;14(9):e15377. DOI:10.15252/emmm.202115377
   PubMed Web of Science ®Google Scholar
• Matte U, Pasqualim G. Lysosome: the Story Beyond the Storage. J Inherit Metab Dis. 2016;4. DOI:10.1177/2326409816679431
   Google Scholar
• Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6(24):476.
   PubMed Web of Science ®Google Scholar
• Vera LNP, Schuh RS, Fachel FNS, et al. Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR/Cas9 system. J Gene Med. 2022;24(4):e3410. DOI:10.1002/jgm.3410
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. Adv Drug Deliv Rev. 2022;184:114234.
   PubMed Web of Science ®Google Scholar
• Journal of Gene Medicine Database on Gene Therapy Clinical Trials Worldwide. Last accessed Oct 2 2022.
   Google Scholar
• Crystal RG. Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther. 2014;25(1):3–11.
   PubMed Web of Science ®Google Scholar
• Maetzig T, Galla M, Baum C, et al. Gammaretroviral vectors: biology, technology and application. Viruses. 2011;3:677–713.
   PubMed Web of Science ®Google Scholar
• Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–267.
   PubMed Web of Science ®Google Scholar
• Alok VJ, Salemiz S. Pseudotyped Lentiviral Vectors: one Vector, Many Guises. Hum Gene Ther Methods. 2017;28(6):291–301.
   PubMed Web of Science ®Google Scholar
• Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–378.
   PubMed Web of Science ®Google Scholar
• Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14(3):316–327.
   PubMed Web of Science ®Google Scholar
• Chandrasegaran S, Carroll D. Origins of Programmable Nucleases for Genome Engineering. J Mol Biol. 2016;428:963–989.
   PubMed Web of Science ®Google Scholar
• Xue C, Greene EC. DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing. Trends in genetics: tIG. Trends Genet. 2021;37(7):639–656.
   PubMed Web of Science ®Google Scholar
• Urnov FD, Rebar EJ, Holmes MC, et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11:636–646.
   PubMed Web of Science ®Google Scholar
• Christian M, Cermak T, Doyle EL, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics. 2010;186:757–761.
   PubMed Web of Science ®Google Scholar
• Mussolino C, Alzubi J, Fine EJ, et al. Talens facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res. 2014;42:6762–6773.
   PubMed Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, et al. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012;337(6096):816–821. DOI:10.1126/science.1225829
   PubMed Web of Science ®Google Scholar
• Nahmad AD, Reuveni E, Goldschmidt E, et al. Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage. Nature Biotechnol. 40(12). Online ahead of print. 1807–1813. 2022 Jun 30. 10.1038/s41587-022-01377-0.
   PubMed Web of Science ®Google Scholar
• Kim HK, Lee S, Kim Y, et al. High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells. Nat Biomed Eng. 2020;4:111–124.
   PubMed Web of Science ®Google Scholar
• Edraki A, Mir A, Ibraheim R, et al. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for in vivo Genome Editing. Genome Editing Molecular Cell. 2019;73(4):714–726 e4. DOI:10.1016/j.molcel.2018.12.003
   Google Scholar
• Kleinstiver BP, Tsai SQ, Prew MS, et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nature Biotechnol. 2016;34:869–874.
   PubMed Web of Science ®Google Scholar
• Zhang W, Yin J, Zhang-Ding Z, et al. In-depth assessment of the PAM compatibility and editing activities of Cas9 variants. Nucleic Acids Res. 2021;49:8785–8795.
   PubMed Web of Science ®Google Scholar
• Vakulskas CA, Dever DP, Rettig GR, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nature Med. 2018;24:1216–1224.
   PubMed Web of Science ®Google Scholar
• Samuelson C, Radtke S, Zhu H, et al. Multiplex CRISPR/Cas9 genome editing in hematopoietic stem cells for fetal hemoglobin reinduction generates chromosomal translocations. Mol Ther - Methods Clin Dev. 2021;23:507–523.
   PubMed Web of Science ®Google Scholar
• Amendola M, Brusson M, Miccio A. Crisprthripsis: the Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy. Stem Cells Transl Med. 2022;11:1003–1009.
   PubMed Web of Science ®Google Scholar
• Enache OM, Rendo V, Abdusamad M, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nature Genet. 2020;52:662–668.
   PubMed Web of Science ®Google Scholar
• Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420–424.
   PubMed Web of Science ®Google Scholar
• Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–157.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhang XO, Weng Z, et al. Deletion and replacement of long genomic sequences using prime editing. Nature Biotechnol. 2022;40(2):227–234. DOI:10.1038/s41587-021-01026-y
   PubMed Web of Science ®Google Scholar
• Yarnall MTN, Ioannidi EI, Schmitt-Ulms C, et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nature Biotechnol. 2022. Online ahead of print. 10.1038/s41587-022-01527-4
   PubMed Web of Science ®Google Scholar
• Boucher AA, Miller W, Shanley R, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis. 2015;10(1):94. DOI:10.1186/s13023-015-0313-y
   PubMedGoogle Scholar
• Biffi A, Capotondo A, Fasano S, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest. 2006;116(11):3070–3082. DOI:10.1172/JCI28873
   PubMed Web of Science ®Google Scholar
• Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet. 2016;388(10043):476–487. DOI:10.1016/S0140-6736(16)30374-9
   PubMed Web of Science ®Google Scholar
• Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158.
   PubMed Web of Science ®Google Scholar
• Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022;399(10322):372–383. DOI:10.1016/S0140-6736(21)02017-1.
   PubMed Web of Science ®Google Scholar
• Meneghini V, Frati G, Sala D, et al. Generation of Human Induced Pluripotent Stem Cell-Derived Bona Fide Neural Stem Cells for Ex vivo Gene Therapy of Metachromatic Leukodystrophy. Stem Cells Transl Med. 2017;6(2):352–368. DOI:10.5966/sctm.2015-0414
   PubMed Web of Science ®Google Scholar
• Doerr J, Bockenhoff A, Ewald B, et al. Arylsulfatase a Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy. Mol Ther. 2015;23(9):1519–1531. DOI:10.1038/mt.2015.106
   PubMed Web of Science ®Google Scholar
• Allewelt H, Taskindoust M, Troy J. Long-Term Functional Outcomes after Hematopoietic Stem Cell Transplant for Early Infantile Krabbe Disease. Biol Blood Marrow Transplant. 2018;24(11):2233–2238.
   PubMed Web of Science ®Google Scholar
• Visigalli I, Ungari S, Martino S, et al. The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche. Blood. 2010;116:1857–1866.
   PubMed Web of Science ®Google Scholar
• Gentner B, Visigalli I, Hiramatsu H, et al. Identification of Hematopoietic Stem Cell–Specific miRnas Enables Gene Therapy of Globoid Cell Leukodystrophy. Sci Transl Med. 2010;2(58):58ra84. DOI:10.1126/scitranslmed.3001522
   PubMed Web of Science ®Google Scholar
• Ungari S, Montepeloso A, Morena F, et al. Design of a regulated lentiviral vector for hematopoietic stem cell gene therapy of globoid cell leukodystrophy. Mol Ther Methods Clin Dev. 2015;2:15038.
   PubMed Web of Science ®Google Scholar
• Hu P, Li Y, Nikolaishvili-Feinberg N, et al. Hematopoietic Stem cell transplantation and lentiviral vector-based gene therapy for Krabbe’s disease: present convictions and future prospects. J Neurosci Res. 2016;94(11):1152–1168. DOI:10.1002/jnr.23847
   PubMed Web of Science ®Google Scholar
• Stirnemann J, Belmatoug N, Camou F, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci. 2017;18(2):441. DOI:10.3390/ijms18020441
   PubMed Web of Science ®Google Scholar
• Donald A, Bjorkvall CK, Vellodi A, et al. Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease. Orphanet J Rare Dis. 2022;17(1):234. DOI:10.1186/s13023-022-02378-7
   PubMed Web of Science ®Google Scholar
• Dunbar CE, Kohn DB, Schiffmann R, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther. 1998;9:2629–2640.
   PubMed Web of Science ®Google Scholar
• Kim EY, Hong YB, Lai Z, et al. Long-term expression of the human glucocerebrosidase gene in vivo after transplantation of bone-marrow-derived cells transformed with a lentivirus vector. J Gene Med. 2005;7(7):878–887. DOI:10.1002/jgm.732
   PubMed Web of Science ®Google Scholar
• Enquist IB, Nilsson E, Ooka A, et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A. 2006;103(37):13819–13824. DOI:10.1073/pnas.0606016103
   PubMed Web of Science ®Google Scholar
• Enquist IB, Nilsson E, Mansson JE, et al. Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells. 2009;27(3):744–752. DOI:10.1634/stemcells.2008-0844
   PubMed Web of Science ®Google Scholar
• Dahl M, Smith EMK, Warsi S, et al. Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector. Mol Ther Methods Clin Dev. 2021;20:312–323.
   PubMed Web of Science ®Google Scholar
• Scharenberg SG, Poletto E, Lucot KL, et al. Engineering monocyte/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing. Nat Commun. 2020;11(1):3327. DOI:10.1038/s41467-020-17148-x.
   PubMed Web of Science ®Google Scholar
• Takenaka T, Qin G, Brady RO, et al. Circulating alpha-galactosidase a derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. Hum Gene Ther. 1999;10(12):1931–1939. DOI:10.1089/10430349950017293
   PubMed Web of Science ®Google Scholar
• Takenaka T, Hendrickson CS, Tworek DM, et al. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol. 1999;27(7):1149–1159. DOI:10.1016/S0301-472X(99)00050-8
   PubMed Web of Science ®Google Scholar
• Yoshimitsu M, Higuchi K, Ramsubir S, et al. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther. 2007;14(3):256–265. DOI:10.1038/sj.gt.3302839
   PubMed Web of Science ®Google Scholar
• Ohshima T, Murray GJ, Swaim WD, et al. α-Galactosidase a deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A. 1997;94(6):2540–2544. DOI:10.1073/pnas.94.6.2540
   PubMed Web of Science ®Google Scholar
• Pacienza N, Yoshimitsu M, Mizue N, et al. Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther. 2012;20(7):1454–1461. DOI:10.1038/mt.2012.64
   PubMed Web of Science ®Google Scholar
• Khan A, Barber DL, Huang J, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun. 2021;12(1):1178. DOI:10.1038/s41467-021-21371-5
   PubMed Web of Science ®Google Scholar
• Kami D, Suzuki Y, Yamanami M, et al. Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease. Cell Transplant. 2021;30:9636897211060269.
   Web of Science ®Google Scholar
• Nagree MS, Felizardo TC, Faber ML, et al. Autologous, lentivirus-modified, T-rapa cell “micropharmacies” for lysosomal storage disorders. EMBO Mol Med. 2022;14(4):e14297. DOI:10.15252/emmm.202114297
   PubMed Web of Science ®Google Scholar
• Ramsubir S, Nonaka T, Girbes CB, et al. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab. 2008;95(3):133–141. DOI:10.1016/j.ymgme.2008.08.003
   PubMed Web of Science ®Google Scholar
• Walia JS, Neschadim A, Lopez-Perez O, et al. Autologous Transplantation of Lentivector/Acid Ceramidase–Transduced Hematopoietic Cells in Nonhuman Primates. Hum Gene Ther. 2011;22(6):679–687. DOI:10.1089/hum.2010.195
   PubMed Web of Science ®Google Scholar
• Schuchman EH, Desnick RJ. Types a and B Niemann-Pick disease. Mol Genet Metab. 2017;120(1–2):27–33.
   PubMed Web of Science ®Google Scholar
• Jin HK, Schuchman EH. Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of niemann–pick disease. Mol Ther. 2003;8(6):876–885.
   PubMed Web of Science ®Google Scholar
• Sano R, Tessitore A, Ingrassia A, et al. Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood. 2005;106:2259–2268.
   PubMed Web of Science ®Google Scholar
• Tsunogai T, Ohashi T, Shimada Y, et al. Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis. Mol Ther Methods Clin Dev. 2022;25:448–460.
   PubMed Web of Science ®Google Scholar
• Syres K, Harrison F, Tadlock M, et al. Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood. 2009;114:2542–2552.
   PubMed Web of Science ®Google Scholar
• Harrison F, Yeagy BA, Rocca CJ, et al. Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis. Mol Ther. 2013;21(2):433–444. DOI:10.1038/mt.2012.214
   PubMed Web of Science ®Google Scholar
• Naphade S, Sharma J, Gaide Chevronnay HP, et al. Brief reports: lysosomal cross-correction by hematopoietic stem cell-derived macrophages via tunneling nanotubes. Stem Cells. 2015;33:301–309.
   PubMed Web of Science ®Google Scholar
• Kohler L, Puertollano R, Raben N. Pompe Disease: from Basic Science to Therapy. Neurotherapeutics. 2018;15:928–942.
   PubMed Web of Science ®Google Scholar
• Douillard-Guilloux G, Richard E, Batista L, et al. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of α-glucosidase in Pompe disease. J Gene Med. 2009;11(4):279–287. DOI:10.1002/jgm.1305
   PubMed Web of Science ®Google Scholar
• van Til Np, Stok M, Aerts Kaya FSF, et al. Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood. 2010;115(26):5329–5337. DOI:10.1182/blood-2009-11-252874
   PubMed Web of Science ®Google Scholar
• Stok M, de Boer H, Huston MW, et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease. Mol Ther Methods Clin Dev. 2020;17:1014–1025.
   PubMed Web of Science ®Google Scholar
• Piras G, Montiel-Equihua C, Chan YA, et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease. Mol Ther Methods Clin Dev. 2020;18:558–570.
   PubMed Web of Science ®Google Scholar
• Liang Q, Vlaar EC, Catalano F, et al. Lentiviral gene therapy prevents anti-human acid alpha-glucosidase antibody formation in murine Pompe disease. Mol Ther Methods Clin Dev. 2022;25:520–532.
   PubMed Web of Science ®Google Scholar
• D’avanzo F, Rigon L, Zanetti A, et al. Mucopolysaccharidosis Type II: one Hundred Years of Research, Diagnosis, and Treatment. Int J Mol Sci. 2020;21(4):1258.
   PubMed Web of Science ®Google Scholar
• Kubaski F, Yabe H, Suzuki Y, et al. Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II. Biol Blood Marrow Transplant. 2017;23:1795–1803.
   PubMed Web of Science ®Google Scholar
• Sonoda H, Morimoto H, Yoden E, et al. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. Mol Ther. 2018;26:1366–1374.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Hendriksz CJ, Fan Z, et al. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med. 2016;18:73–81.
   PubMed Web of Science ®Google Scholar
• High KA, Roncarolo MG. Gene Therapy. N Engl J Med. 2019;381:455–464.
   PubMed Web of Science ®Google Scholar
• Shull RM, Lu X, McEntee MF, et al. Myoblast Gene Therapy in Canine Mucopolysaccharidosis I: abrogation by an Immune Response to α - l -Iduronidase. Hum Gene Ther. 1996;7(13):1595–1603. DOI:10.1089/hum.1996.7.13-1595
   PubMed Web of Science ®Google Scholar
• Ohashi T, Yokoo T, Iizuka S, et al. Reduction of lysosomal storage in murine mucopolysaccharidosis type VII by transplantation of normal and genetically modified macrophages. Blood. 2000;95:3631–3633.
   PubMed Web of Science ®Google Scholar
• Sakurai K, Iizuka S, Shen JS, et al. Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice. Genet Ther. 2004;11(19):1475–1481. DOI:10.1038/sj.gt.3302338
   PubMed Web of Science ®Google Scholar
• Meyerrose TE, Roberts M, Ohlemiller KK, et al. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells. 2008;26:1713–1722.
   PubMed Web of Science ®Google Scholar
• Walton RM, Magnitsky SG, Seiler GS, et al. Transplantation and magnetic resonance imaging of canine neural progenitor cell grafts in the postnatal dog brain. J Neuropathol Exp Neurol. 2008;67:954–962.
   PubMed Web of Science ®Google Scholar
• Miki T, Vazquez L, Yanuaria L, et al. Induced Pluripotent Stem Cell Derivation and Ex vivo Gene Correction Using a Mucopolysaccharidosis Type 1 Disease Mouse Model. Stem Cells Int. 2019;2019:6978303.
   PubMed Web of Science ®Google Scholar
• Griffin TA, Anderson HC, Wolfe JH. Ex vivo gene therapy using patient iPSC-derived NSCs reverses pathology in the brain of a homologous mouse model. Stem Cell Rep. 2015;4:835–846.
   PubMed Web of Science ®Google Scholar
• Gentner B, Tucci F, Galimberti S, et al. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. N Engl J Med. 2021;385:1929–1940.
   PubMed Web of Science ®Google Scholar
• Fraldi A, Hemsley K, Crawley A, et al. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet. 2007;16:2693–2702.
   PubMed Web of Science ®Google Scholar
• Langford-Smith A, Wilkinson FL, Langford-Smith KJ, et al. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol Ther. 2012;20:1610–1621.
   PubMed Web of Science ®Google Scholar
• Ruzo A, Marco S, Garcia M, et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther. 2012;23(12):1237–1246. DOI:10.1089/hum.2012.029
   PubMed Web of Science ®Google Scholar
• Sergijenko A, Langford-Smith A, Liao AY, et al. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther. 2013;21:1938–1949.
   PubMed Web of Science ®Google Scholar
• Ellison SM, Liao A, Wood S, et al. Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA. Mol Ther - Methods Clin Dev. 2019;13:399–413.
   PubMed Web of Science ®Google Scholar
• Parker H, Ellison SM, Holley RJ, et al. Haematopoietic stem cell gene therapy with IL-1Ra rescues cognitive loss in mucopolysaccharidosis IIIA. EMBO Mol Med. 2020;12:e11185.
   PubMed Web of Science ®Google Scholar
• Holley RJ, Ellison SM, Fil D, et al. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. Brain. 2018;141:99–116.
   PubMed Web of Science ®Google Scholar
• Marechal V, Naffakh N, Danos O, et al. Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells. Blood. 1993;82:1358–1365.
   PubMed Web of Science ®Google Scholar
• Hofling AA, Devine S, Vogler C, et al. Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol Ther. 2004;9:856–865.
   PubMed Web of Science ®Google Scholar
• Lutzko C, Omori F, Abrams-Ogg AC, et al. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. Hum Gene Ther. 1999;10(9):1521–1532. DOI:10.1089/10430349950017851
   PubMed Web of Science ®Google Scholar
• Rothe M, Modlich U, Schambach A. Biosafety challenges for use of lentiviral vectors in gene therapy. current Gene Therapy. 2013;13(6):453–468.
   PubMed Web of Science ®Google Scholar
• Gomez-Ospina N, Scharenberg SG, Mostrel N, et al. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nat Commun. 2019;10:4045.
   PubMed Web of Science ®Google Scholar
• Poletto E, Colella P, Pimentel Vera LN, et al. Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation. Mol Ther - Methods Clin Dev. 2022;25:392–409.
   PubMed Web of Science ®Google Scholar
• Han JF, El-Amouri SS, Dai M, et al. Getting the Most: enhancing Efficacy by Promoting Erythropoiesis and Thrombopoiesis after Gene Therapy in Mice with Hurler Syndrome. Mol Ther - Methods Clin Dev. 2018;11:52–64.
   PubMed Web of Science ®Google Scholar
• Dai M, Han J, El-Amouri SS, et al. Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome. Proceedings of the National Academy of Sciences. 2014;111(7):2680–2685.
   PubMed Web of Science ®Google Scholar
• Miwa S, Watabe AM, Shimada Y, et al. Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy. Mol Gene Metabol. 2020;130:262–273.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang W, Kalfa TA, et al. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proceedings of the National Academy of Sciences. 2009;106(47):19958–19963.
   PubMed Web of Science ®Google Scholar